|Day's range||32.75 - 32.75|
At the ASCO meeting, Illumina (ILMN) is set to showcase data that highlights better outcomes for cancer patients who receive comprehensive genomic testing.
Brussels has accused Illumina of using “delay tactics” to prevent a speedy ruling on whether the world’s biggest gene sequencing company should be forced to divest cancer test developer Grail. It follows repeated claims by Illumina that it is moving as “expeditiously as possible” to resolve litigation linked to its $8bn acquisition of Grail, which is the focus of a bruising proxy battle waged by Carl Icahn, the veteran activist investor. US antitrust regulators also ordered Grail’s divestiture in April, a decision Illumina is appealing against.
Insiders were net sellers of Illumina, Inc.'s ( NASDAQ:ILMN ) stock during the past year. That is, insiders sold more...
Plus, the battle heats up between Icahn and Illumina and Cayman Islands defends itself as a go-to for the super-rich
Vote to remove John Thompson is the culmination of one of the largest shareholder activism campaigns in years
(Bloomberg) -- Illumina Inc. shareholders voted to elect a board member nominated by activist shareholder Carl Icahn, a much-needed partial victory for the billionaire as his investment firm grapples with an attack by short-seller Hindenburg Research. Most Read from BloombergCathie Wood’s ARKK Dumped Nvidia Stock Before $560 Billion SurgeApple Plans to Turn Locked iPhones Into Smart Displays With iOS 17JPMorgan Tells 1,000 First Republic Employees They'll Lose Their JobsFirst Republic’s $35 Mill
Illumina is strong enough to survive the loss of its chair John Thompson and chief executive Francis deSouza if shareholders vote them down at an annual meeting on Thursday, a director of the company has said. Gary Guthart told the Financial Times there was depth on the board and management of the world’s biggest gene sequencing company beyond the two executives, who had been targeted in a proxy battle waged by activist investor Carl Icahn.
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Let's talk about the popular Illumina, Inc. ( NASDAQ:ILMN ). The company's shares received a lot of attention from a...
As an investor its worth striving to ensure your overall portfolio beats the market average. But if you try your hand...
Key Insights Illumina's estimated fair value is US$164 based on 2 Stage Free Cash Flow to Equity Illumina is estimated...
Illumina (NASDAQ: ILMN) and Bionano Genomics (NASDAQ: BNGO) might both make gene sequencing devices, but as investments the two couldn't be more different. Whereas Bionano is a new entrant to the market and still has a lot to prove to its investors as well as the scientific community, Illumina is the top dog that's fighting to maintain its position. Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation sequencers (NGS).
The gene-sequencing company reported weaker results while the Federal Trade Commission has ordered it to divest its Grail acquisition.
Illumina's (ILMN) Q1 revenues decline year over year, reflecting the impact of Covid-19 monitoring headwinds and the transition of its high-throughput customers to NovaSeq X.
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Illumina (ILMN) delivered earnings and revenue surprises of 300% and 2.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
EXEL vs. ILMN: Which Stock Is the Better Value Option?
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
For example, over the last five years, Illumina's (NASDAQ: ILMN) stock is down nearly 5%. For those who aren't familiar, Illumina is the undisputed king of the gene sequencer hardware market, to where many accept it as a quasi-monopoly. When healthcare systems or research laboratories need to analyze genetic material, the company's devices are the industry's standard, and it has a product in every segment of the market.
Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.
Illumina, Inc. ( NASDAQ:ILMN ) saw a double-digit share price rise of over 10% in the past couple of months on the...
With shares of Illumina (NASDAQ: ILMN) down 37% over the last 12 months and underperforming the market over the last five years, shareholders have had a rough time. As of April 3, regulators in the U.S. were rebuffing its acquisition of Grail, a cancer-testing company that it originally founded and spun off. While some competitors make devices that do the same thing as Illumina's products, there's certainly no rising star anywhere in sight that could take its place.
Illumina's (ILMN) recent collaboration is built on the shared goal of the organizations to expand sequencing capabilities and capacity for all people in Africa.
Illumina's (ILMN) NovaSeq X records the strongest pre-launch demand ever witnessed for any instrument.